Skip to main content
Premium Trial:

Request an Annual Quote

Dmitry Samarsky, Steven Tregay

Premium
RXi, the RNAi subsidiary of CytRx, has named Dmitry Samarsky as its vice president of technology development.
 
Samarsky was most recently director of technology development at Dharmacon, a unit of Thermo Fisher Scientific. Prior to that, he was business development manager at Invitrogen.
 
Earlier in his career, Samarsky held various business development roles at Sequitur, an RNAi reagent company acquired by Invitrogen and founded by RXi’s president and CEO, Tod Woolf.
 
Samarsky holds a PhD in biochemistry and molecular biology from the University of Massachusetts, Amherst.
 

 
Adenosine Therapeutics has appointed Steven Tregay to its board of directors.
Tregay is a managing director of the Novartis Option Fund and was recently named a director of Cequent Pharmaceuticals.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.